Related Experiment Video
Updated: Jul 9, 2026

Implantation of Osmotic Pumps and Induction of Stress to Establish a Symptomatic, Pharmacological Mouse Model for DYT/PARK-ATP1A3 Dystonia
Published on: September 12, 2020
Novel GCH1 mutation in a Brazilian family with dopa-responsive dystonia
Sarah Teixeira Camargos1, Francisco Cardoso, Parastoo Momeni
1Universidade Federal de Minas Gerais, Department of Clinical and Neurological Sciences, Movement Disorders Group, Brazil.
Abstract:
Dopa responsive Dystonia (DRD) was first described in 1971 and typically begins at childhood with gait dysfunction caused by foot dystonia progressing to affect other extremities. There is marked diurnal fluctuation and sustained improvement of symptoms with low dose levodopa therapy. Heterozygous mutation of the gene GCH1 has been shown to cause DRD. We studied GCH1 in nine patients with DRD from six families of Federal University of Minas Gerais Movement Disorders Clinic. We identified three mutations; two affected siblings carried a novel T209P mutation and two siblings from another family were compound heterozygous carriers of Met211Val and Lys224Arg mutations. To our knowledge this is the first report of GCH1 mutations underlying DRD in patients from Brazil.
More Related Videos
Related Concept Videos
Huntington Disease l: Introduction
Alterations in Muscle Tone ll
Incomplete Dominance
Parkinson Disease ll: Pathophysiology
Parkinson Disease l: Introduction
Alterations in Muscle Tone lll

